PaySign shares fell 18.9% after earnings, with the planned loss of payment processing at 113 plasma centers likely weighing on investors despite rapid patient-affordability growth. The transition is expected to be completed in Q4, and management said it expects new centers to offset the loss over the next couple of quarters.
- Revenue rose 43% year over year to $30.8 million; net income increased more than 200% to $6.7 million, or $0.11 per diluted share.
- Patient-affordability revenue more than doubled to $16.6 million, with claim volume up approximately 55%; revenue per program rose about 32% to $99,500.
- Gross margin expanded 840 basis points to 64.7%, as patient affordability became a larger share of revenue.
- PaySign launched 19 programs in Q3 and had 167 active programs; it expects to end 2026 with 190–195.
- Plasma revenue increased 7.5% to $13.8 million, but the company expects to end the year with 445–450 centers, down from 562 at quarter-end, following the customer transition.
Community Discussion